What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)”In the company’s words, NCT05838092 on ClinicalTrials.gov
- Tested for
- Epidermolysis Bullosa (2 trials)
- Main trialPhase 3
- “The aim of this clinical trial is to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with recessive dystrophic epidermolysis bullosa (RDEB) compared to placebo. An additional baseline-controlled open-label arm will be included to investigate the safety and efficacy of allo-APZ2-OTS administered intravenously to subjects with JEB and to RDEB subjects \< 1 year.”In the company’s words, NCT05838092 on ClinicalTrials.gov
Other drugs for Epidermolysis Bullosa
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 29 Aug 2025 | Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III) | |
| Phase 3Active, not recruiting | 29 Aug 2025 | Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026